SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending after Sanofi announced its acquisition for $15.50 per share, a move set to bolster Sanofi's adult immunization portfolio with Dynavax's hepatitis B vaccine and a shingles candidate. This news has sparked significant trading volume, with many long-term holders expressing disappointment over the acquisition price while also discussing the company's recent licensing deal for an oral COVID-19 vaccine program.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT CRYPTO is trending amidst strong community discussion, largely fueled by its close association with Coinbase's #base platform and recent listing on Robinhood. Investors are actively debating its potential as a leading perpetual decentralized exchange, emphasizing its RWA trading features and high leverage offerings, despite some volatility and skepticism regarding past performance. The prevailing sentiment anticipates significant growth, positioning AVNT as a key player in the evolving crypto landscape.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics is trending after receiving a Complete Response Letter (CRL) from the FDA for its lead drug candidate, OLC, which cited manufacturing deficiencies at a third-party vendor, not issues with the drug's efficacy or safety. The community is weighing the short-term delay and potential for future dilution against OLC's strong clinical profile and the company's plan to resubmit for possible approval in the first half of the coming year. Many investors see this as a long-term opportunity, emphasizing that the drug's core benefits for dialysis patients remain intact despite regulatory setbacks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending as the market digests news of new government contracts and its significant revenue backlog in the high-performance AI computing space. Community discussion is vibrant, with bulls pointing to strong demand and key industry backing, while others express caution regarding its substantial debt and recent insider share divestment.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

DRV is currently trending as the community actively discusses its significant collaboration with Synthetix to develop derivatives on Ethereum, signaling strong foundational growth. Traders are closely watching its 'slow and steady' performance and 'Onchain Matrix' tokenomics, anticipating further upside following recent consolidation and buyback discussions.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy (EOSE) is trending amid discussions around its recent strategic financing and the U.S. Department of Energy taking a warrant, which bulls view as a significant derisking event to scale manufacturing for AI data centers and grid demands. While community sentiment is mixed on execution risk and dilution concerns, many anticipate substantial growth in the long-duration energy storage market. The company's unique non-lithium battery technology positions it to capitalize on increasing demand and government incentives, with focus on its path to consistent profitability.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is generating significant discussion driven by its strategic partnership to integrate at-home exam technology and speculation surrounding substantial government initiatives in rural healthcare. While many express acute frustration regarding current leadership and past capital allocation, a strong bullish contingent believes the company is deeply undervalued and poised for a major rebound as a global leader in the rapidly expanding AI healthcare sector.

StoneCo Ltd. engages in the provision of financial technology solutions. It caters to merchants and partners that conduct electronic commerce across in-store, online, and mobile channels. The firm offers cloud-based technology platform, electronic payments, and automation of business processes at the point-of-sale. The company was founded by André Street de Aguiar in 2000 and is headquartered in George Town, Cayman Islands.

StoneCo Ltd - Ordinary Shares - Class A

StoneCo Ltd

StoneCo is trending following strong recent earnings beats, significant share buyback programs, and the strategic divestiture of its Linx software business to sharpen focus on the core MSMB segment. Community discussion highlights robust operational execution and impressive growth in areas like Pix adoption, alongside an attractive valuation. However, volatility and concerns about Brazil's political climate, including new fintech taxes, remain central to investor sentiment.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is trending following multiple positive regulatory milestones, including recent FDA approvals for expanded uses of its key drugs Libtayo in skin cancer and Eylea HD for retinal vein occlusion, alongside promising late-stage clinical trial results for garetosmab. The community is buzzing with optimism about the company's robust pipeline and a strong earnings beat, with many investors viewing the stock as an undervalued powerhouse despite some lingering concerns regarding manufacturing facility delays.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending amid significant volatility, as ongoing insider selling and debates about upcoming lockup expirations pressure the stock, which has fallen sharply from its IPO highs. Community discussion is split between those who view the current levels as a major buying opportunity due to strong product adoption and past acquisition interest from Adobe, and others concerned about continued valuation issues and competitive threats, particularly regarding AI's impact on its creative software niche.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Xxggvin

XXGG